Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis: Syndecan-1, glypican-3 and ICP
ConclusionSyndecan-1 and glypican-3 might be powerful determinants in predicting adverse perinatal outcome in patients with ICP, and they can be used to predict the response to the UDCA treatment.
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
More News: Bile | Cholestasis | Gastroenterology | Obstetric Cholestasis | Pancreas | Perinatology & Neonatology | Pregnancy | Study | Women